Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Subscribe To Our Newsletter & Stay Updated